Artivion, Inc. (AORT) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 11, 2026
Artivion, Inc. (AORT)
A forensic read on Artivion, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Safe
Financial health
5.1
Distress distance
Clean
Earnings quality
4
Forensic signals
115.0
P / E (ttm)
2.2%
ROE
$1.3B
Market cap
13.6%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Artivion, Inc. earns a C (Mixed — selective) forensic quality grade, and its balance-sheet distress test reads 5.1, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
3.1%
FY2025
Return on invested capital.Return on invested capital is 3.1% in the latest fiscal year and rising from 1% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+5.6%/yr
FY2022–FY2025
Share-count dilution.Diluted share count changed +18% over the last 3 years to FY2025 (+5.6%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~5.6% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~15%.
6% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 6% of revenue and 2906% of free cash flow in FY2025 — about $0.52 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count: holders gave up about 5.7% of the company a year, and that rate is not falling. That is the figure to weigh, not the share of free cash flow.
+10.8%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +10.8% relative to their own average in FY2025 — scaled by NOA itself, not total assets (see the Forensic Screens card's differently-scaled Sloan Accrual Ratio for that read). Accruals are building faster than is comfortable — part of profit is sitting in the balance sheet rather than turning to cash. The build is led by inventory up +16% against +12% in cost of sales and receivables up +13% against revenue +14%. The cash-flow cross-check is more mixed: reported earnings ran behind operating cash by 5% of net operating assets, diverging from the balance-sheet accrual read.
Key fundamentals
Latest Revenue$441.3M
Revenue Growth YoY+13.6%
Revenue CAGR (3yr)+12.0%
Net Margin2.2%
Free Cash Flow$839,000.00
Return on Equity2.2%
Debt / Equity0.48x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Artivion, Inc.'s actual 10-K/10-Q/8-K filings?